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Environmental Ethics
The U.S. Environmental Protection Agency (EPA) held the first
meeting on environmental ethics sponsored by the Scientific
Advisory Panel and Board on 10-11 December 1998 in Arlington,
Virginia (1). The report from the meeting will more completely
inform scientists and the community of current issues. This editori-
al should serve as an initial briefofthis meeting [which was held on
the fiftieth anniversary ofthe Declaration ofHuman Rights (adopt-
ed by the United Nations on 10 December 1948)].
A number ofchemical pesticide manufacturers now use human
subjects in their pesticide studies. This is to ascertain and develop
biomarkers, to examine agricultural worker exposure, and primarily
to better understand human exposure and risk. The human studies,
many in other countries, are an attempt to establish new safety fac-
tors, usually to implement the broader use of a pesticide or to estab-
lish human no-observed-adverse-effect levels (NOAELs) for new
agents being developed. Much of the justification for these private
human research studies is based on the human drug paradigm.
Further, these studies are typically presented to the EPA without
their prior knowledge and without standing EPA human studies
and ethics committees to review these studies. If an ethics commit-
tee were active, the accepted ethical basis of these studies would be
the "Common Rule" or policy [40 CFR 26 (2); less restrictive than
the Helsinki Dedaration (3) orArtide Five ofthe Nuremberg Code
(4), which requires researchers to participate in their own studies;
Common Rule also urges more children and women to participate,
which would not be operative in this scenario. Surprisingly, it has
also been reported that pesticide patch tests have been performed on
teenagers with parental approval, and pesticides have been adminis-
tered to patients withAlzheimer diseaseX(1,5)].
Criteria for various human studies are available, but they vary
from country to country if not hospital to hospital (institutional
review boards, who are already overburdened, may suffer conflict of
interest when approving internal studies oftheir colleagues). Given
these complexities that bedevil the hospital and medical school
human research communities, it seems that criteria for human stud-
ies are quite new and complex in agribusiness and in the regulatory
community, where a long tradition ofhuman studies does not exist.
One primary use for these studies is regulatory. These studies are
not instituted to improve general or population health care directly
(like a drug), nor are they constructed to improve the health of an
individual suffering from a disease. These agents are accepted as
toxic, and their regulatory toxicology (not scientific toxicology) is
being defined. These studies fall into "risk-risk" assessment, not
"risk-benefit," which is the classical model ofdrug study design. It is
not common practice to administer a toxic compound; for example,
we do not administer lead to children to ascertain risk [although his-
torically lead was administered to adults to ascertain risk (1)]. Some
"trivial risk" studies with ozone have been performed, but these must
be examined individually. It is a matter of concern that known toxic
agents, many ofwhich are neurotoxic, have been administered, even
when the state of the scientific art at this time cannot demonstrate
harm (although with future tech-
nology, harm may be more evi-
dent); even the smallest details of
' \ \these decisions must be questioned. _ Z }@ These studies should not be per-
formed without a complete review
ofall ofthe animal studies available
(typically voluminous and some-
times overlooked). Further, use of these agents with the intent to
alter existing regulations should not be allowed without a complete
review ofpoison control center reports, in which thousands ofcases
are recorded (although they are not reported under accepted human
studies circumstances).
Another major concern is remuneration: organizations that per-
form these studies recruit people who may receive $600-800/week,
but, at the initial time ofrecruitment, the subjects may not appreciate
what agents theywill be exposed to. This quandary is avoided bypay-
ing people for time spent, not for the actual risk exposure of the
experiment. Also, money is used to reward agents for supplying
patients; this offers opportunities for ethical conflict. Many of these
volunteers will likely be people from lower socioeconomic levels who
will not derive direct significant personal benefit, or people who have
already been exposed to high levels ofother similar agents (e.g., agri-
cultural workers and their families, or residents of inner-city urban
areas where indoor air quality, pesticides, and vermicides may be evi-
dent, although this may not be documented before testing or other
experimental exposures). Although "proper" informed consent may
be obtained during experimental initiation, the concept ofduress by
economic incentive cannot be dismissed. Obviously, few if any of
these studies are initiated by investigators who normallyachieve fund-
ing from independent agencies. These studies are most often con-
ceived by corporations who seek investigators (and pay them well)
(1); are these investigators able to avoid corporate influence and bias?
Further, these studies typically remain unpublished and exist as confi-
dential information for the company; these studies would have to be
duplicated by another company developing similar products before
the results could be released (still not to the public, because these
results are "confidential business"). This also raises ethical concerns.
Even ifa small population is recruited for these pesticide studies
(usually 4 controls and 12 experimental patients), they are usually
not applicable to children, the elderly, and certain patients on heart,
psychiatric, or neurologic drugs. These are huge populations, as are
all ofthe special populations in the United States.
Regarding possible consideration and justification for human
testing, the actual chemical and agricultural industry workers who
produce the pesticides in factories, as well as farm workers and their
families (children can be many times overexposed to these agents)
are stakeholders in human studies. They understand that the results
ofhuman studies may applyvery directly to them. Ultimately, these
types of studies should only be allowed when no alternatives are
available.
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We appear to be in an early era of environmental human test-
ing. Similarly, when we were in this era in genetic research (far more
cogent to humans who were suffering from diseases for which the
gene or its product would lead to cure), we called a moratorium on
human research until our social and ethics policies could catch up
(these policies are coupled and must move forward in tandem).
Human exposure to pesticide testing and experimentation are not
warranted without a stringent ethical review. Further, it is time for
the EPA to consider developing a standing ethics committee
(including reviews of animal testing) and an institutional review
board to better understand these matters and to give guidance to
corporations (foreign and domestic), scientists, and potential volun-
teers. This ethics committee must include community representa-
tion, and it must also set leadership standards in this murky, newly
evolving arena. There is an overarching concern to educate investi-
gators, regulators, and corporations in the need to incorporate the
ethos ofethics in their human and animal studies trials on a regular
basis. If all of these lofty issues are resolved (although the practical
matter ofhealth insurance has not been resolved, and compensation
for complications or untoward sequelae of pesticide testing is
nonexistent), the EPA, wise in its understanding to initiate this dia-
logue, should establish a standing Ethics and Human Studies
Committee, answerable to the administrator, who should exercise
prudent oversight on all matters referred to the committee from
both inside and outside the agency.
The opinions stated in this editorial are the authors own and do not represent any
organization.
JacobJ. Steinberg
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PAS proteins have been shown to be part of the signal
transduction pathways controlling such diverse biological
functions as circadian rhythms, cell fate determination,
response to hypoxia, response to dioxin, and light sensing.
This meeting is designed to bring together scientists involved
in these diverse areas of PAS protein research in order to ISV/I?
disseminate the most up-to-date research and to allow investigators
employing different techniques and model organisms to share informa-
tion andbenefit from unique scientific approaches.
Session topics include PAS domain structure-function, Ah receptor and dioxin
toxicology, PAS proteins as light sensors in plants, hypoxia signal transduction
pathways, PAS proteins as components of the biological clock controlling
circadian rhythms, PAS proteins as developmental signals, and emerging sig-
naltransduction pathways involving PAS proteins.
Confirmed speakers include Alan Poland, Oliver Hankinson, Chris
Bradfield, Greg Semenza, G. Clark Lagarias, Michael Chan, Lorenz Peollinger,
Michael Rosbash, Jay Dunlap, Yoshiaki Fugi-Kuriyama, M. Celeste Simon, Ian
Duncan, Tom Wilson, Steve Crews, andWilliam Atchley.
For more information on the meeting, to present a poster, to apply for a young
investigator travel award, or to register for the meeting (no registration fee), send
yourname, affiliation, address, e-mailaddress, andphone numberto:
Jerry Heindel, 919-541-0781, e-mail: jhl90f@nih.gov
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